Wall Street analysts forecast that Incyte Co. (NASDAQ:INCY) will announce earnings of ($0.50) per share for the current quarter, according to Zacks Investment Research. Twenty analysts have provided estimates for Incyte’s earnings. The highest EPS estimate is $0.09 and the lowest is ($0.68). Incyte reported earnings per share of $0.15 during the same quarter last year, which would suggest a negative year over year growth rate of 433.3%. The firm is scheduled to report its next earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Incyte will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.49) to ($1.00). For the next financial year, analysts forecast that the firm will post earnings of $0.17 per share, with EPS estimates ranging from ($1.83) to $1.98. Zacks’ EPS averages are an average based on a survey of analysts that cover Incyte.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. During the same period in the prior year, the company earned $0.19 earnings per share. The company’s revenue was up 41.6% compared to the same quarter last year.

INCY has been the subject of several analyst reports. BMO Capital Markets cut their price target on Incyte from $163.00 to $162.00 and set an “outperform” rating for the company in a research note on Thursday, October 26th. Royal Bank of Canada cut their price target on Incyte from $136.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 21st. Oppenheimer set a $135.00 price target on Incyte and gave the stock a “hold” rating in a research note on Tuesday, October 31st. JPMorgan Chase & Co. restated a “buy” rating on shares of Incyte in a research note on Tuesday, October 31st. Finally, Deutsche Bank initiated coverage on Incyte in a research note on Tuesday, December 12th. They set a “hold” rating and a $106.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $143.11.

Incyte (INCY) traded up $1.01 during trading on Tuesday, hitting $94.07. The stock had a trading volume of 1,572,700 shares, compared to its average volume of 1,833,222. Incyte has a twelve month low of $92.52 and a twelve month high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The stock has a market capitalization of $19,440.00, a PE ratio of -117.59 and a beta of 0.74.

In other news, insider David W. Gryska sold 3,915 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul A. Friedman sold 28,507 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 44,878 shares of company stock valued at $4,636,494. Company insiders own 17.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in INCY. Nordea Investment Management AB boosted its stake in shares of Incyte by 0.8% during the second quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 67 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Incyte by 13.8% during the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Incyte by 1.9% during the second quarter. Ameritas Investment Partners Inc. now owns 7,571 shares of the biopharmaceutical company’s stock valued at $953,000 after acquiring an additional 143 shares during the last quarter. AMP Capital Investors Ltd boosted its stake in shares of Incyte by 0.7% during the third quarter. AMP Capital Investors Ltd now owns 72,076 shares of the biopharmaceutical company’s stock valued at $8,414,000 after acquiring an additional 500 shares during the last quarter. Finally, Hanseatic Management Services Inc. boosted its stake in shares of Incyte by 6.8% during the second quarter. Hanseatic Management Services Inc. now owns 7,924 shares of the biopharmaceutical company’s stock valued at $998,000 after acquiring an additional 506 shares during the last quarter. Institutional investors and hedge funds own 90.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Incyte Co. (INCY) Expected to Post Earnings of -$0.50 Per Share” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/16/incyte-co-incy-expected-to-post-earnings-of-0-50-per-share.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.